FARMAKOGENOMIKA I REGULACIJA APOPTOZE U AKUTNOJ MIJELOIDNOJ LEUKEMIJI: KRATAK PREGLEDNI ČLANAK
Ključne reči:
AML, farmakogenomika, ara-C, antraciklini, apoptoza
Sažetak
Akutna mijeloidna leukemija (AML) je klonalna bolest hematolopeze, heterogena kako u etipoatogenetskom tako i u smislu ishoda lečenja. Osnov terapije predstavlja kombinacija citarabina (ara-C) i antraciklina. Uprkos visokoj stopi remisija, posebno kod mlađih, većina bolesnika umire zbog relapsa ili usled komplikacija izazvanih hemioterapijom/transplantacijom matične ćelije hematopoeze. Nepovoljna prognoza AMLse jednim delommože objasniti genetskom varijabilnošću bolesnika. Cilj ovog preglednog članka je prikaz uticaj genetskih polimorfizama metaboličkih puteva citarabina i antraciklina, kao i proteina uključenih u regulaciju apoptoze na efikasnost i toksičnost lečenja AML.
Reference
1. Hatipoglu OF, Bender O, Gunduz E, Gunduz M. Pharmacogenomics in Acute Myeloid Leukemia. In: Barh D, Dhawan D, Ganguly N, editors. Omics for Personalized Medicine. New Delhi: Springer; 2013. p.237-48.
2. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129(4):424-47.
3. Maksimovic N, Zaric M, Gazibara T, et al. Incidence and Mortality Patterns of Acute Myeloid Leukemia in Belgrade, Serbia (1999–2013). Medicina (Kaunas) 2018;54(1):5.
4. Isidori A, Loscocco F, Curti A, Amadori S, Visani G. Genomic profiling and predicting treatment response in acute myeloid leukemia. Pharmacogenomics. 2019;20(7):467-470.
5. Emadi A, Karp JE. The clinically relevant pharmacogenomic changes in acute myelogenous leukemia. Pharmacogenomics 2012;13(11):1257-69.
6. Mlakar V, Huezo-Diaz Curtis P, Satyanarayana Uppugunduri CR, et al. Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use. Int J Mol Sci 2016;17(9):1502.
7. Megías-Vericat JE, Montesinos P, Herrero MJ, et al. Pharmacogenomics and the treatment of acute myeloid leukemia. Pharmacogenomics 2016;17(11):1245-72.
8. Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics 2009; 10(10):1657–74.
9. Wan H, Zhu J, Chen F, et al. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res. 2014;33(1):90.
10. Megías-Vericat JE, Rojas L, Herrero MJ, et al. Influence ofABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies. Pharmacogenomics 2015;15:109–118.
11. Lubieniecka JM, Graham J, Heffner D et al. A discoverystudy of daunorubicin induced cardiotoxicity in a sampleof acute myeloid leukemia patients prioritizes P450oxidoreductase polymorphisms as a potential risk factor. Front Genet 2013;4:231.
12. Xiao Q, Deng D, Li H, et al. GSTT1 and GSTM1 polymorphisms predict treatment outcome for acute myeloid leukemia: a systematic review and meta-analysis. Ann Hematol. 2014;93(8):1381-1390.
13. Megias-Vericat JE, Martinez-Cuadron D, Herrero MJ, et al. Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia. Curr Drug Metab 2018;19(1):55-74.
14. Kulsoom B, Shamsi TS, Afsar NA, et al. Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy? Cancer Manag Res 2018; 10:403-16.
15. Prokop A, Wieder T, Sturn I, et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia. 2000;14:1606–1613.
16. Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood. 1999;93:2671–2678.
17. Köhler T, Schill C, Deininger MW, et al. High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). Leukemia. 2002;16:22–29.
18. Aref S, Salama O, Al-Tonbary Y, Mansour A. Assessment of bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia. Hematology. 2004;9:113–121.
19. Kornblau SM, Thall PF, Estrov Z, et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999; 5:1758–1766.
20. Del Poeta G, Venditti A, Del Principe MI, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood. 2003;101:2125–2131.
21. Guerra VA, DiNardo C, Konopleva M. Venetoclax-based Therapies for Acute Myeloid Leukemia. BestPract Res Clin Haematol. 2019;32(2):145–153.
2. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129(4):424-47.
3. Maksimovic N, Zaric M, Gazibara T, et al. Incidence and Mortality Patterns of Acute Myeloid Leukemia in Belgrade, Serbia (1999–2013). Medicina (Kaunas) 2018;54(1):5.
4. Isidori A, Loscocco F, Curti A, Amadori S, Visani G. Genomic profiling and predicting treatment response in acute myeloid leukemia. Pharmacogenomics. 2019;20(7):467-470.
5. Emadi A, Karp JE. The clinically relevant pharmacogenomic changes in acute myelogenous leukemia. Pharmacogenomics 2012;13(11):1257-69.
6. Mlakar V, Huezo-Diaz Curtis P, Satyanarayana Uppugunduri CR, et al. Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use. Int J Mol Sci 2016;17(9):1502.
7. Megías-Vericat JE, Montesinos P, Herrero MJ, et al. Pharmacogenomics and the treatment of acute myeloid leukemia. Pharmacogenomics 2016;17(11):1245-72.
8. Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics 2009; 10(10):1657–74.
9. Wan H, Zhu J, Chen F, et al. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res. 2014;33(1):90.
10. Megías-Vericat JE, Rojas L, Herrero MJ, et al. Influence ofABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies. Pharmacogenomics 2015;15:109–118.
11. Lubieniecka JM, Graham J, Heffner D et al. A discoverystudy of daunorubicin induced cardiotoxicity in a sampleof acute myeloid leukemia patients prioritizes P450oxidoreductase polymorphisms as a potential risk factor. Front Genet 2013;4:231.
12. Xiao Q, Deng D, Li H, et al. GSTT1 and GSTM1 polymorphisms predict treatment outcome for acute myeloid leukemia: a systematic review and meta-analysis. Ann Hematol. 2014;93(8):1381-1390.
13. Megias-Vericat JE, Martinez-Cuadron D, Herrero MJ, et al. Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia. Curr Drug Metab 2018;19(1):55-74.
14. Kulsoom B, Shamsi TS, Afsar NA, et al. Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy? Cancer Manag Res 2018; 10:403-16.
15. Prokop A, Wieder T, Sturn I, et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia. 2000;14:1606–1613.
16. Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood. 1999;93:2671–2678.
17. Köhler T, Schill C, Deininger MW, et al. High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). Leukemia. 2002;16:22–29.
18. Aref S, Salama O, Al-Tonbary Y, Mansour A. Assessment of bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia. Hematology. 2004;9:113–121.
19. Kornblau SM, Thall PF, Estrov Z, et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999; 5:1758–1766.
20. Del Poeta G, Venditti A, Del Principe MI, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood. 2003;101:2125–2131.
21. Guerra VA, DiNardo C, Konopleva M. Venetoclax-based Therapies for Acute Myeloid Leukemia. BestPract Res Clin Haematol. 2019;32(2):145–153.
Objavljeno
2020/12/31
Broj časopisa
Rubrika
Mini pregledni članak